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Abstract
Background: The study was performed to investigate the expression of chemokine receptors (CR) on circulating
tumor cells (CTC), which may be of importance for organ-specific metastases and cancer treatment since CR are
potential drug-targets.
Methods: Blood samples from patients with metastatic carcinoma (MC) or melanoma (MM) were enriched for CTC
and expression of CR (CXCR4, CCR6, CCR7 and CCR9) was evaluated by flow cytometry.
Results: CTC were detected in 49 of 68 patients (72%) [28 MC; 21 MM] with a median number of 3 CTC (range: 1-
94)/10 mL of blood. CXCR4 was expressed on CTC in 82% (40/49) of patients [median number 1 CTC/10 mL blood;
range 1-14] and CCR6 in 29 patients (59%; median 1, range: 1-14). In MM patients, CCR7 was expressed on CTC in
6 (29%) samples and CCR9 in 12 (57%). A positive correlation between surface expression of CR and organ-specific
metastatic pattern was not observed.
Conclusions: CR were expressed on CTC of patients with solid tumors. Along with our findings, the observation
that CR could be involved in CTC proliferation and migration of tumor cells appoints CTC as potential CR-
antagonist therapeutic target.
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Background
The presence of circulating tumor cells (CTC) was first
described in 1869 by Thomas Ashworth. Cells similar to
the ones of the tumor were observed in the blood of a
man with metastatic cancer [1]. Despite improvements
in isolation and in characterization of CTC, the current
understanding of their biological properties is very lim-
ited. It is in fact totally unclear, whether CTC are a frac-
tion of cells transiently present in the blood stream as a
prerequisite to potentially seed haematogenous metas-
tases of the disease, or represent a unique subpopulation
of tumor cells able to survive and circulate in the blood
stream for an extended duration, perhaps with the
potential to eventually home to peripheral tissues, where
t h e ym a yo rm a yn o tb ea b l et oi n i t i a t ef o r m a t i o no f
metastases (i.e. possess complete metastasis-initiating
properties).
Presence of tumor cells in the circulation does not
necessary end up with development of metastasis and its
growth could be a phenomenon due to random survival
of few tumor cells. In a mouse model it has indeed been
shown that less than 0.1% of tumor cells of the primary
tumor survived in blood to produce metastases [2].
However, although CTC might be simply shed in the
circulation without having a clinical impact, a significant
correlation between the presence of CTC and develop-
ment of distant metastases and outcome has been
observed by several groups [3-7].
Metastases show in the majority of cases an organ-
specific pattern of spread and this specificity is indepen-
dent from any anatomical factor. In 1889 Stephen Paget
analyzed 735 autopsy records of women with breast can-
cer and a non-random pattern of organ metastases was
observed. Paget’s results led to the formulation of the so
called “seed and soil theory” [8]. The process of metas-
tasis seemed therefore not due to chance, but to the fact
that tumor cells (the ‘seed’) had a specific affinity for the
microenvironment of certain organs (the ‘soil’). Different
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any medium, provided the original work is properly cited.organs have special abilities to arrest, attract, and pro-
mote certain types of cancer cells which matched the
specific microenvironment of the host tissue. A major
mechanism in the seed concept is that metastatic cancer
cells co-opt chemokine-mediated signalling (seed-factor),
which normally controls leukocyte distribution.
Chemokines display pleiotropic effects in immunity,
regulating angiogenesis, promoting proliferation of
tumor cells and mediating organ-specific metastases [9].
Several different chemokine receptors (CR), including
CXCR4 [10-15], CCR7 [16-18], CCR9 [19] and CCR6
[20,21], have been suggested to mediate metastasis to
specific target-organs and the presence of a specific CR
on cancer cells has been associated with a definite meta-
static pattern.
In particular, high levels of functional CXCR4 recep-
tors have been observed on human breast cancer cells
and correspondingly, the highest CXCR4 ligand expres-
sion, CXCL12, was detected in organs that are preferen-
tial destinations of breast cancer metastasis [10]. Other
studies supported the idea that the CXCR4/CXCL12
axis is the principle mechanism for marrow homing of
normal or malignant cells and may therefore regulate
migration and metastasis of a variety of cancer types
including melanoma and colon cancer [11-15]. Expres-
sion of CCR7 in tumor cells of patients with non-small-
cell lung cancer or colon cancer has been correlated
with the ability of the cells to spread to the lymph
nodes [16,17]. In a previous study we observed a strong
correlation between functional CCR9 expression in mel-
anoma and the occurrence of intestinal metastases [19].
Similarly, we observed a striking correlation between
CCR6 overexpression and synchronous liver metastasis
in patients with colorectal carcinoma [20].
In this study we conducted an exploratory analysis to
evaluate whether CTC enriched from patients with solid
tumors expressed the CR CXCR4, CCR6, CCR7 and
CCR9. Correlation between expression of CR and meta-
static pattern was also evaluated.
Methods
Samples collection
The investigation was approved by the Ethic Committee
at Charité. Sixty-eight consecutive patients receiving var-
ious forms of systemic chemotherapy at Charité (Berlin,
Germany) were enrolled: 29 were affected by metastatic
melanoma [MM] and 39 by metastatic carcinoma [MC].
Twenty mL blood anticoagulated with heparin was col-
lected after informed consent from each patient. Blood
was collected before treatment start irrespective of the
line of treatment. Samples were drawn after discarding
the first 2 mL of blood to avoid potential skin cell con-
tamination from venipuncture and processed within 1
hour after sampling.
Enrichment (CD45 depletion) for CTC
Red blood cell lysis buffer (154 mM NH4Cl, 10 mM
KHCO3 and 0.1 mM EDTA in deionized water) was
used to lyse erythrocytes. Cells were subsequently
washed with a buffer consisting of phosphate-buffered
saline (PBS) containing 0.5% bovin serum albumin
(BSA), and 2 mM ethylenediaminetetraacetic acid
(EDTA). Cells were counted and resuspended in the
buffer at a concentration of 1 × 10
8 cells/mL and then
enriched for tumor cells by CD45 depletion of the leu-
kocyte fraction using a magnetic bead separation techni-
que (EasySep
®, Stem Cells Technologies, Inc.,
Vancouver, BC, Canada) as previously described [22].
The remaining material was split in two fractions and
stained with either a cocktail of specific antibodies or
with the corresponding isotypic control antibodies pur-
chased from the same manufacturer. All antibody
batches were titrated to determine their optimal concen-
tration. Specificity, recovery and linearity of the method
have been previously reported [22-24].
Characterization of CTC for CR expression by flow
cytometry
In case of carcinomas cells were stained on the surface
with a cocktail containing EpCAM (0.006 mg/mL;
c l o n eE B A - 1 ,B DB i o s c i e n c e s ,S a nJ o s é ,C A ,U S A ) ,
CXCR4 (0.002 mg/mL; clone 12 G5; BD Biosciences);
CCR6 (0.002 mg/mL; clone R6H1, eBiosciences San
Diego, CA, USA) and CD45 (0.015 mg/mL clone
TU116, BD Biosciences). For intracellular staining
cells were fixed with 1% formaldehyde and thereafter
permeabilized. Briefly, pellet was resuspended in 2 mL
of a sterile solution containing 0.1% saponin, 0.05%
NaN3 in Hanks’ Balanced Salt Solution (SAP buffer).
Cells were centrifuged at 200 × g for 5 minutes;
supernatant decanted ensuring that approximately 200
μL of SAP buffer remained in the tube. Cells were
subsequently stained with antibodies specific for cyto-
keratin (CK) 7 and 8 (0.01 mg/mL clone CAM 5.2, BD
Biosciences) and incubated for 20 minutes in the dark
at 4°C.
In case of melanoma, cells were stained on the surface
with melanoma-associated chondroitin sulphate proteo-
glycan (Miltenyi Biotec Inc., Auburn CA, USA, CD45
(clone TU116, BD Biosciences), CXCR4 (BD Bios-
ciences); CCR6 (eBiosciences); CCR7 (0.002 mg/mL;
Clone 150503, R&D System, Minneapolis, MN USA)
and CCR9 (0.002 mg/mL; clone 112509, R&D System).
Cells were acquired on a FACSCanto II system (BD
Biosciences) and the whole volume was evaluated.
Potential epithelial cells were defined as EpCAM and
CK double-positive and CD45 negative. Potential mela-
noma cells were defined as melanoma-associated chon-
droitin sulphate proteoglycan-positive and CD45
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Statistical analysis
Chi-squared or Fisher’s exact test tests were used where
appropriate to evaluate any differences between the
parameters examined. Two-sided p < 0.05 was consid-
ered to be statistically significant. The analysis was per-
formed using SPSS Inc. Software (version 18.0).
Results
Patients and detection of CTC
CTC were detected in the blood of 49 patients (72%): 28
out of 39 (72%) MC patients and 21 out of 29 (72%)
MM patients showed at least 1 CTC/10 mL blood.
Characteristics of the patients included in the analysis
on CR expression (positive for presence of CTC) are
listed in Table 1.
The median number of CTC was 3 (range: 1-94)/10
mL. The median number of CTC was 2 (range: 1-21)/10
mL blood in the MC cohort and 4 (range: 1-94)/10 mL
blood in the MM group.
Expression of chemokine receptors on CTC
Results were summarized in Table 2 and depicted in
Figure 1. CXCR4 was expressed on CTC in 82% (40/49)
of the patients and the median number of CXCR4-posi-
tive CTC was 1 (range: 1-14). CCR6 was expressed in
29 patients (59%) and the median number of CCR6posi-
tive CTC was 1 (range: 1-14). Expression rates of
CXCR4 and CCR6 did not significantly differ between
MC and MM patients (Figure 1). CXCR4 was more fre-
quently expressed on CTC than CCR6 (p = 0.015; Fig-
ure 1).
CCR7 was expressed on CTC in 6 MM patients (6/21
= 29%) and the median number of CCR7-positive CTC
was 1 (range: 1-5). CCR9 was expressed on CTC in 12
MM patients (57%) and the median number of CCR7-
positive CTC was 2 (range: 1-5).
Seventeen (61%) patients with MC presented CTC
double positive for CXCR4 and CCR6; 7 (25%) patients
showed CTC positive for CXCR4 or CCR6 and 4 (14%)
had CTC negative for both the CXCR4 and CCR6. The
median number of CTC without expression of CXCR4
and CCR6 was 1 (range: 1-18). Fourteen (66%) patients
affected by MM presented CTC positive for at least two
of the CR analysed; 3 (14%) patients showed CTC posi-
t i v ef o ro n l yo n eC Ra n d4( 1 9 % )r e s u l t e dt oh a v eC T C
negative for expression of all the CR evaluated. The
median number of CTC negative for all the CR analysed
was 6 (range 3-86).
Expression of chemokine receptors on CTC and
metastatic pattern
We then asked if expression of the CR on CTC corre-
lated with presence of liver metastasis or lung metasta-
sis. Results are presented in Table 3. No positive
correlation was observed between expression of CR on
CTC and presence of liver or lung metastasis. Results
did not change when MM and MC patients were ana-
lysed separately and when analyses were performed
including only patients with solely liver metastases (n =
15) vs. patients without liver metastasis (data not
shown). Presence of liver or lung metastasis was not
Table 1 Clinical characteristics of the patients included in
the analysis
Total (n =
49)
MC (n =
28)
MM (n =
21)
Age, median (range) 63 (25-85)
Gender (M:F) 25:24
Primary tumor
Colon cancer 9
Breast cancer 5
NSCLC 4
Cervix cancer 3
Ovarian cancer 3
SCCHN 2
Pancreatic cancer 2
Cutaneous Melanoma 11
Uveal melanoma 10
Number of metastatic
sites
12 7
21 5
>2 7
Liver metastasis
Yes 26 11 15
No 23 17 6
Lung metastasis
Yes 22 16 6
No 27 12 15
MC: Metastatic carcinoma; MM: metastatic melanoma; NSCLC: non-small-cell
lung cancer; SCCHN: Head and neck squamous cell carcinoma
Table 2 Median number of chemokine receptor-positive
cells and positivity rates (PR)
Total (n = 49) MC (n = 28) MM (n = 21)
CXCR4 PR
Median [range]
82% (40/49)
1 [1-14]
86% (24/28)
1 [1-14]
76% (16/21)
2 [1-8]
CCR6 PR
Median [range]
59% (29/49)
1 [1-14]
61% (17/28)
1 [1-14]
57% (12/21)
2 [1-8]
CCR7 PR
Median [range]
29% (6/21)
1 [1-5]
CCR9 PR
Median [range]
57% (12/21)
2 [1-5]
MC: Metastatic carcinoma; MM: metastatic melanoma
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ferent CR (data not shown).
Discussion
In the present study, we investigated a series of blood
samples drawn from consecutive metastatic patients
with different solid tumors, in order to evaluate the
expression of the CR CXCR4, CCR6, CCR7 and CCR9
on CTC. CTC expressed CR in the majority of cases,
with CXCR4 being the most frequently expressed CR
and CCR6 often co-expressed.
The studies published so far about this topic are not
directly comparable with our study due to profound dif-
ferences in strategies employed for identification of
CTC. These reports, although more homogeneous in
terms of patients, did not enrich the blood specimens
for CTC and they used a more extensive definition for
CTC identification. Pituch-Noworolska et al. evaluated
the immunophenotype of CK+PBMCs and of dissemi-
nated tumor cells (DTC) from bone marrow in patients
with gastric cancer. CCR6 and CXCR4 expression was
determined on CK+cells sorted out from blood (8 sam-
ples) or bone marrow (69 samples). CCR6 was expressed
in a half of the CK+samples whereas the expression of
CXCR4 was much lower [25]. We also observed expres-
sion of CCR6 in a half of our samples, but unlike
Pituch-Noworolska we observed a much higher expres-
sion of CXCR4. High levels of CXCR4 expression (>
90%) on CK+PBMCs were also observed by other
Figure 1 Expression positivity rates (number of samples in which CR-expressing CTC were observed/number of CTC-positive samples
evaluated) of the chemokine receptors CXCR4, CCR6, CCR7, and CCR9 on CTC in the whole population or in patients with metastatic
carcinoma (MC) or metastatic melanoma (MM). Significant differences are indicated by an asterisk (*).
Table 3 Correlation between chemokine receptor
expression and presence of liver or lung metastases
Liver mestastasis Lung metastasis
Yes (%) No (%) p Yes (%) No (%) p
CXCR4 21/26
(81%)
19/23
(83%)
0.28 17/22
(77%)
23/27
(85%)
0.44
CCR6 14/26
(54%)
15/23
(65%)
0.42 13/22
(59%)
16/27
(62%)
0.84
CCR7 * 5/15 (33%) 1/6 (17%) 0.42 0/6 (0%) 6/15 (40%) 0.09
CCR9 * 9/15 (60%) 3/6 (50%) 0.34 1/6 (17%) 11/15
(73%)
0.03
* only patients with metastatic melanoma
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non-small cell lung cancer [26] or patients with meta-
static renal cancer [27]. For definition of CTC, these
studies used only CK as epithelial marker. Although
there is no reference standard, the definition of epithe-
lial CTC as EpCAM +CK+CD45- we utilized, is the
wider employed and the most accepted. This is indeed
the same definition for identification of CTC applied by
the Cell Search System which was cleared by the FDA
for detection of CTC in some cancer entities. Albeit we
agree that the actual definition might be too restrictive
[22], it has been reported that there are 0-20% CK+
cells in blood samples from normal adults which might
increase the rate of false positive samples and invalidate
the analysis. As first exploratory investigation, we there-
fore decided not to focus on a single cancer type; on the
contrary we preferred to evaluate a broader range of
cancer and a larger spectrum of chemokine receptors.
Despite previous observations of an association
between expression of specific CR in primary tumors
and metastatic organ preference, we did not find any
correlation between CR expression on CTC and specific
metastatic pattern. In our study we evaluated the pre-
sence of CR on the surface of CTC (i.e. ready-to-home
cells) without analysing their intracellular expression.
Intracellular expression of CR (in particular nuclear
expression of CXCR4) assessed at primary tissue level
has been associated to the metastatic destination of
tumor cells and to patient outcome in several different
cancer entities [16-20,28-30]. It might be therefore pos-
sible that we underestimated the quote of CR-positive
CTC. This implies that a further step is needed before
specific cell-seeding: CR already present in the cell
should migrate to the surface. Migration could be
trigged by several mechanisms including unspecific
adhesion [31] and hypoxia [32,33]. Another limitation of
our study consisted in the cohort of patients we ana-
lysed. Blood samples were in fact drawn from patients
with distant metastases affected by different solid
tumors in a relative small number of cases. A substantial
conclusion could not therefore be drawn. An eventual
correlation between CR profile on CTC and metastatic
pattern could have been better assessed in a cohort of
patients with the same tumor entity and before develop-
ment of distant metastasis. The biology of the CTC in
patients with metastasis is poorly investigated, but
recent data suggested they might be a source of further
t u m o rf o c i .M a s s a g u éa n dc o l l e a g u e ss h o w e dt h a tC T C
from distant metastasis were able to re-infiltrate tumors
at their organs of origin and even to promote the
growth of the primary tumors [34]. However, studies
which evaluate expression of more than one CR in
patients with metastatic tumors both at primary and
metastatic level demonstrated a more varied CR expres-
sion at primary level [35-37] compared to metastases
and similar to the expression profile on CTC we
observed. That might denote that the seed (CTC) is
‘equipped’ to migrate potentially anywhere and that the
soil has the principal role in directing migration of the
seed to specific sites. This statement is consistent with
the fact that conditioned media obtained from distinct
tumor types with unique patterns of metastatic spread
redirected premetastatic niche formation, thereby trans-
forming the metastatic profile, in Id3 knockout mice
[38].
Presence of CR on CTC makes CTC a potential thera-
peutic target for CR antagonists. The recent approval of
a CCR5 receptor antagonist in HIV paves in fact the
way for further effective antagonists to other CR. Var-
ious strategies have been employed in preclinical models
to target CXCR4 including inhibitory antibodies, small
molecule antagonists, RNAi and small inhibitory pep-
tides. CXCR4-directed antibodies suppressed lymph
node metastasis in experimental breast cancer [10] and
suppressed tumor growth and impaired the development
of tumor endothelium in experimental models of colon
and pancreatic cancer [39]. Administration of the speci-
fic small molecule CXCR4 antagonist AMD3100 to mice
with intracranial glioblastoma effectively inhibited
growth and increased apoptosis of the tumor cells [40].
Similarly, AMD3100 inhibited ascites accumulation in
an experimental model of gastric cancer [41]. CTCE-
9908 is a peptide analogue of SDF-1 that acts as a com-
petitive antagonist of CXCR4. In experimental models,
treatment with CTCE-9908 showed to reduce tumor
burden, but did not reduce the frequency of metastasis
suggesting that other mechanisms independent from the
expression of CXCR4 are involved in metastasis devel-
opment [42,43]. Although investigation of the role of
CR inhibitors in clinical setting is still in the earlier
phase [44], presence of CXCR4 at high frequency on
CTC of patients with solid tumors makes CTC a poten-
tial therapeutic target for CXCR4 antagonists in a large
number of patients. However, functional assays evaluat-
ing the role of CR in migration and proliferation of
CTC are necessary to assess if a CR inhibition strategy
could be taken into consideration.
Conclusions
CR are expressed on CTC of patients with metastatic
solid tumors. Even though in this study we did not find
a positive correlation between CR expression on CTC
and metastatic pattern, these receptors could be
involved in CTC proliferation and migration of cancer
cells, which appoints CTC as potential CR-antagonist
therapeutic targets.
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